Top

Published in:

Open Access 01-08-2017 | Original Article

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy

Authors: M. K. Boss, M. W. Dewhirst, R. S. Sampaio, A. Bennett, A. Tovmasyan, K. G. Berman, A. W. Beaven, D. A. Rizzieri, I. Batinic-Haberle, M. L. Hauck, I. Spasojevic

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2017

Abstract

Purpose

Manganese porphyrins are redox-active drugs and superoxide dismutase mimics, which have been shown to chemosensitize lymphoma, a cancer which frequently occurs in dogs. This study aimed to identify critical information regarding the pharmacokinetics and toxicity of Mn(III) meso-tetrakis (N-n-butoxyetylpyridium-2-yl) porphyrin, (MnTnBuOE-2-PyP⁵⁺, MnBuOE) in dogs as a prelude to a clinical trial in canine lymphoma patients.

Methods

A single-dose pharmacokinetic (PK) study in normal dogs was performed to determine the plasma half-life (t _1/2) of MnBuOE. A dose reduction study was performed to establish the maximum tolerated dose (MTD) of MnBuOE. The safety and PK of a multi-dosing protocol was assessed.

Results

Peak plasma drug concentration occurred 30 min post-injection. The t _1/2 was defined as 7 h. MnBuOE induced an anaphylactic reaction and prolonged tachycardia. The MTD was defined as 0.25 mg/kg. The dogs were given MTD 3×/week for 2–3 weeks. The highest recorded tissue drug levels were in the lymph nodes (4–6 μM), followed by kidney and liver (2.5, 2.0 uM, respectively).

Conclusions

We obtained critical information regarding the PK and toxicity of MnBuOE in dogs. The acute drug reaction and tachycardia post-injection have not been described in other species and may be specific to canines. The high tissue drug levels in lymph nodes have not been previously reported. MnBuOE accumulation in lymph nodes has important implications for the utility of adjuvant MnBuOE to treat lymphoma. With MnBuOE lymph node accumulation, reduction in the dose and/or administration frequency could be possible, leading to reduced toxicity.

Available only for authorised users

Moeller BJ, Cao YT, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5(5):429–441. doi:10.1016/s1535-6108(04)00115-1 CrossRefPubMed

Il’yasova D, Kennedy K, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, Marcom PK, Marks J, Millington DS, Dewhirst MW (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125(2):583–589. doi:10.1007/s10549-010-1158-7 CrossRefPubMed

Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3):223–242. doi:10.1016/j.etp.2008.09.003 CrossRefPubMed

Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132(1):109–119. doi:10.1007/s10549-011-1568-1 CrossRefPubMed

Ashcraft KA, Boss MK, Tovmasyan A, Roy Choudhury K, Fontanella AN, Young KH, Palmer GM, Birer SR, Landon CD, Park W, Das SK, Weitner T, Sheng H, Warner DS, Brizel DM, Spasojevic I, Batinic-Haberle I, Dewhirst MW (2015) Novel manganese-porphyrin superoxide dismutase-mimetic widens the therapeutic margin in a preclinical head and neck cancer model. Int J Radiat Oncol Biol Phys 93(4):892–900. doi:10.1016/j.ijrobp.2015.07.2283 CrossRefPubMedPubMedCentral

Weitzel DH, Tovmasyan A, Ashcraft KA, Rajic Z, Weitner T, Liu C, Li W, Buckley AF, Prasad MR, Young KH, Rodriguiz RM, Wetsel WC, Peters KB, Spasojevic I, Herndon JE, Batinic-Haberle I, Dewhirst MW (2015) Radioprotection of the brain white matter by Mn(III) N-Butoxyethylpyridylporphyrin—Based superoxide dismutase mimic MnTnBuOE-2-PyP5+. Mol Cancer Ther 14(1):70–79. doi:10.1158/1535-7163.mct-14-0343 CrossRefPubMed

Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Rebouças JS, Batinic-Haberle I, Vujaskovic Z (2010) Early and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage. Free Radical Biol Med 48(8):1034–1043. doi:10.1016/j.freeradbiomed.2010.01.020 CrossRef

Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Batinic-Haberle I, Vujaskovic Z (2008) Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radical Biol Med 44(6):982–989. doi:10.1016/j.freeradbiomed.2007.10.058 CrossRef

Moeller BJ, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Anscher MS, Vujaskovic Z, Dewhirst MW (2005) A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys 63(2):545–552. doi:10.1016/j.ijrobp.2005.05.026 CrossRefPubMed

10.

Batinic-Haberle I, Tovmasyan A, Roberts ERH, Vujaskovic Z, Leong KW, Spasojevic I (2014) SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal 20(15):2372–2415. doi:10.1089/ars.2012.5147 CrossRefPubMedPubMedCentral

11.

Jaramillo MC, Frye JB, Crapo JD, Briehl MM, Tome ME (2009) Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Can Res 69(13):5450–5457. doi:10.1158/0008-5472.can-08-4031 CrossRef

12.

Jaramillo MC, Briehl MM, Batinic-Haberle I, Tome ME (2015) Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radical Biol Med 83:89–100. doi:10.1016/j.freeradbiomed.2015.01.031 CrossRef

13.

Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11(16):5984–5992. doi:10.1158/1078-0432.ccr-05-0577 CrossRefPubMed

14.

Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan ZY, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16(4):324–335. doi:10.1016/j.ccr.2009.08.015 CrossRefPubMedPubMedCentral

15.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ (2016) Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology. Sci Trans Med 8(324):324–325CrossRef

16.

Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18(8):781–792. doi:10.3109/07357900009012210 CrossRefPubMed

17.

Richards KL, Motsinger-Reif AA, Chen HW, Fedoriw Y, Fan C, Nielsen DM, Small GW, Thomas R, Smith C, Dave SS, Perou CM, Breen M, Borst LB, Suter SE (2013) Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, Modeling Human DLBCL. Cancer Res 73(16):5029–5039. doi:10.1158/0008-5472.can-12-3546 CrossRefPubMedPubMedCentral

18.

Richards KL, Suter SE (2015) Man’s best friend: what can pet dogs teach us about non-Hodgkin’s lymphoma? Immunol Rev 263(1):173–191. doi:10.1111/imr.12238 CrossRefPubMedPubMedCentral

19.

Rajic Z, Tovmasyan A, Spasojevic I, Sheng HX, Lu MM, Li AM, Gralla EB, Warner DS, Benov L, Batinic-Haberle I (2012) A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity. Free Radical Biol Med 52(9):1828–1834. doi:10.1016/j.freeradbiomed.2012.02.006 CrossRef

20.

Tovmasyan A, Carballal S, Ghazaryan R, Melikyan L, Weitner T, Maia CGC, Reboucas JS, Radi R, Spasojevic I, Benov L, Batinic-Haberle I (2014) Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents. Inorg Chem 53(21):11467–11483. doi:10.1021/ic501329p CrossRefPubMedPubMedCentral

21.

Gad SC, Sullivan DW Jr, Spasojevic I, Mujer CV, Spainhour CB, Crapo JD (2016) Nonclinical Safety and Toxicokinetics of MnTnBuOE-2-PyP5+ (BMX-001). Int J Toxicol. doi:10.1177/1091581816642766

22.

Tovmasyan A, Sampaio RS, Boss MK, Bueno-Janice JC, Bader BH, Thomas M, Reboucas JS, Orr M, Chandler JD, Go YM, Jones DP, Venkatraman TN, Haberle S, Kyui N, Lascola CD, Dewhirst MW, Spasojevic I, Benov L, Batinic-Haberle I (2015) Anticancer therapeutic potential of Mn porphyrin/ascorbate system. Free Radic Biol Med 89:1231–1247. doi:10.1016/j.freeradbiomed.2015.10.416 CrossRefPubMedPubMedCentral

23.

Batinic-Haberle I, Tovmasyan A, Spasojevic I (2016) Mn porphyrin-based redox-active therapeutics. In Redox-Active Therapeutics. Springer International Publishing, Switzerland. doi:10.1007/978-3-319-30705-3_8 CrossRef

24.

Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, Vujaskovic Z, Dewhirst MW, Piganelli JD (2012) Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids 42(1):95–113. doi:10.1007/s00726-010-0603-6 CrossRefPubMed

25.

Platt R, Ng T, Glover S, Roof M, Kimura K, Roth JA (2013) Canine peripheral blood lymphocyte phenotyping by 7-color multiparameter flow cytometry. Anal Quant Cytol Histol 35(4):197–204

Title: Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy
Authors: M. K. Boss
M. W. Dewhirst
R. S. Sampaio
A. Bennett
A. Tovmasyan
K. G. Berman
A. W. Beaven
D. A. Rizzieri
I. Batinic-Haberle
M. L. Hauck
I. Spasojevic
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3372-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients

Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine?

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer